HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Moderna Inc (MRNA US) - Insights About the Performance in Front of Omicron

Brii Biosciences (2137.HK) - With the Potential of “Zero to One”

Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?

Beijing Wantai Biological (603392.CH) - How to Support Its High Valuation?

CanSino Biologics (688185.CH/6185.HK) 2021/1H - Concerns on Key Products and the Outlook

Chongqing Zhifei Biological Products (300122.CH) - Could Zhifei Support Its Valuation?

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Chongqing Zhifei Biological Products / Equity Bottom-Up

Chongqing Zhifei Biological Products (300122 CH)

<p>After hitting a record high of RMB230.69/share in May this year, <a href="https://www.smartkarma.com/entities/chongqing-zhifei-biological-products-co-ltd" target="_blank" data-smartkarma-citation="entities:6245:1" rel="noopener">Chongqing Zhifei Biological Products (300122 CH)</a>'s share price fell nearly 35% and closed at RMB150.20/share as of Oct. 29, 2021. Meanwhile, last week, Zhifei released its 2021Q3 results. The revenue was RMB21.829 billion, up 98% YoY, and net profit was RMB8.404 billion, up 239% YoY, indicating that the Company kept strong growth momentum. However, compared with 2021Q2, the revenue and net profit attributed to shareholders in Q3 single quarter was decreased by 6.3% and 36%, respectively. This insight mainly analyzed some concerns behind the high growth of Zhifei.  </p>

After hitting a record high of RMB230.69/share in May this year, Chongqing Zhifei Biological Products (300122 CH)'s share price fell nearly 35% and closed at RMB150.20/share as of Oct. 29, 2021. Meanwhile, last week, Zhifei released its 2021Q3 results. The revenue was RMB21.829 billion, up 98% YoY, and net profit was RMB8.404 billion, up 239% YoY, indicating that the Company kept strong growth momentum. However, compared with 2021Q2, the revenue and net profit attributed to shareholders in Q3 single quarter was decreased by 6.3% and 36%, respectively. This insight mainly analyzed some concerns behind the high growth of Zhifei.  

Chongqing Zhifei Biological Products (300122.CH) 2021Q3 - Concerns Behind the High Growth